论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Wang LL, Li Y, Li LC, Wu ZJ, Yang D, Ma HW, Wang DL
Received 22 November 2017
Accepted for publication 26 February 2018
Published 26 April 2018 Volume 2018:11 Pages 2345—2353
DOI https://doi.org/10.2147/OTT.S157755
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Purpose: This study was conducted to compare the efficacy of a combination
of icotinib and chemotherapy with icotinib or chemotherapy alone in untreated
non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor
receptor (EGFR)-sensitive mutations and to analyze the curative effect of
different treatments on different genetic mutations (EGFR 19 exon deletion and
L858R mutation) in a real-life setting.
Patients and methods: One
hundred ninety-one patients were studied in this retrospective analysis from
January 2013 to December 2015. The baseline characteristics, curative effects
and adverse events of patients were analyzed. The primary endpoint was
progression free survival (PFS).
Results: Longer PFS and overall survival (OS), and better
objective response rate (ORR) were observed in the combination group compared
to icotinib or chemotherapy along. For patients with an EGFR 19 exon deletion,
the PFS, OS, and ORR in the combination group were superior to those in the
icotinib or chemotherapy group. For the patients with the EGFR L858R mutation,
better PFS and ORR were observed in the combination group, but OS was not
obviously prolonged. Grade 3 or 4 adverse events were most commonly reported
with combination therapy or chemotherapy alone. No possible drug-related
interstitial lung disease or of drug related deaths occurred.
Conclusion: The combination of icotinib and chemotherapy in
patients with untreated NSCLC harboring sensitive EGFR mutations resulted in
improved PFS and OS, especially in those who harbored the EGFR exon 19
deletion.
Keywords: non-small-cell
lung cancer, EGFR-TKI, icotinib, chemotherapy, first-line treatment